Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
Authors: Weerawat Manosuthi
Somnuek Sungkanuparph
Preecha Tantanathip
Wiroj Mankatitham
Aroon Lueangniyomkul
Supeda Thongyen
Boonchuay Eampokarap
Sumonmal Uttayamakul
Pawita Suwanvattana
Samroui Kaewsaard
Kiat Ruxrungtham
Thailand Ministry of Public Health
Mahidol University
The HIV Netherlands Australia Thailand Research Collaboration
Bamrasnaradura Infectious Diseases Institute
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Oct-2009
Citation: Antimicrobial Agents and Chemotherapy. Vol.53, No.10 (2009), 4545-4548
Abstract: Seventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored. The mean ± standard deviation efavirenz C12 at weeks 6 and 12 and after rifampin discontinuation were 4.5 ± 4.3, 3.8 ± 3.5, and 3.5 ± 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = -0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg. Copyright © 2009, American Society for Microbiology. All Rights Reserved.
ISSN: 10986596
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.